17.01.2025.
Leading pharmaceutical and IT companies have said they will quit Ireland if a proposed ban on so-called forever chemicals is introduced.
The ongoing debate over the proposed EU-wide ban on so-called “forever chemicals” has sparked significant concern among some of Ireland’s leading industries. Pharmaceutical and IT companies, which form the backbone of Ireland’s economy, are warning that such a move could push them to relocate their operations.
What is PHAS?
These substances, formally known as per- and polyfluoroalkyl substances (PFAS), are used in a vast array of products due to their durability and resistance to heat, water, and oil.
However, their persistence in the environment has raised alarm bells, as they do not break down naturally and are linked to various health and environmental risks.
According to the European Environment Agency,
PFOS is one of the approximate 10,000 compounds in the large group of PFAS, also known as ‘forever chemicals’ due to their extreme persistence in the environment. Based on 2022 data from about 1,300 monitoring sites in Europe, 59% of sites in rivers, 35% of sites in lakes, and 73% of sites in transitional and coastal waters exceeded the environmental quality standard for PFOS.
Industries voice frustration
The proposed ban, set for consideration in early 2025, could have profound implications for industries dependent on these chemicals.
Ireland, a hub for pharmaceutical and IT companies, faces a potential economic fallout if key players in these sectors choose to move to more favourable regulatory environments.
With multinational companies like Intel, Pfizer, and others deeply integrated into the Irish economy, the stakes are high.
These businesses rely on PFAS in critical manufacturing processes, including semiconductor production, medical device coatings, and specialized pharmaceutical applications.
Industry leaders argue that an outright ban, without adequate alternatives or a phased implementation plan, could render some manufacturing processes unfeasible.
For example, PFAS are integral in creating high-performance materials used in semiconductors and drug delivery systems.
Without these substances, maintaining the current level of innovation and production could prove challenging. As a result, some companies have hinted at potential downsizing or even relocation, which would deal a heavy blow to Ireland’s employment and economic growth.
Ireland’s government is caught in a difficult position. On one hand, environmental advocacy groups and public health experts emphasize the urgent need to address the long-term damage caused by PFAS, which has been detected in water supplies and is linked to serious health concerns such as cancer and hormonal disruption.
On the other hand, the potential exodus of major corporations presents an economic and political challenge.
With over 300,000 jobs tied to the pharmaceutical and IT sectors and significant contributions to Ireland’s GDP, the government must balance environmental responsibility with economic stability.
What is the EU proposing
The EU’s proposed ban is part of a broader strategy to address harmful chemicals under the European Green Deal.
While the specifics of the ban are still under discussion, exemptions for critical industries and applications have been proposed to mitigate immediate disruptions.
However, industry representatives argue that the timeline for identifying and deploying safe alternatives is insufficient.
The current EU policy target under the Water Framework Directive is to achieve good chemical status for Europe’s water bodies by 2027. According to the EEA’s recent ‘Europe’s state of water’ assessment, only 29% of Europe’s waters achieved good chemical status over the 2015-2021 period. The EU zero pollution vision for 2050 is for air, water and soil pollution to be reduced to levels no longer considered harmful to health and natural ecosystems.
In the coming months, Ireland’s leadership will need to engage in active dialogue with both the EU and industry stakeholders to seek a viable path forward.
Policymakers are exploring potential compromises, such as extended deadlines for compliance or investments in research to develop safer alternatives to PFAS.
Additionally, there is a push to ensure that any regulatory changes include provisions to protect Ireland’s competitive edge in the global market.
The outcome of this debate will not only shape the future of Ireland’s pharmaceutical and IT sectors but also serve as a litmus test for how nations balance environmental priorities with industrial and economic needs.
For now, the country’s industries, government, and environmental advocates remain locked in a complex negotiation, with far-reaching implications for Ireland’s economic and ecological landscape.
